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ABSTRACT 
Objective: Klebsiella pneumoniae is highly prevalent in hospitals and causes many nosocomial infections. The study sought to determine prevalence 
rates of extended spectrum β-lactamases (ESBLs) in clinical isolates of K. pneumoniae from Cairo, Egypt and to detect the ESBL-encoding genes in 
the isolates.  
Methods: K. pneumoniae isolates were collected through two-year period (2011-2012). Identification of K. pneumoniae was carried out using 
automated Microscan and standard biochemical tests. ESBL pattern and minimum inhibitory concentrations (MICs) were detected using Clinical 
and Laboratory Standards Institute guidelines and confirmatory tests. Multiplex polymerase chain reaction for ESBL-encoding genes and plasmid 
profiling were performed. 
Results: In the present work; 112 isolates, 75 of them from cancer patients, were characterized. High proportion (52 of 112, “46 %”) of ESBLs 
among the isolates were detected. Highest prevalence of ESBLs was seen among cancer patients, 39 isolates of 75 (52%). Plasmid profile for ESBL-
producing K. pneumoniae isolates showed different sizes and numbers of plasmids in all isolates. MICs for all ESBL-producing isolates revealed high 
resistance rates with tetracycline (100%), cefepime (96%), gentamycin (90%) and ciprofloxacin (79%). Whereas, only two isolates (4%) were 
resistant to both carbapenem drugs tested, imipenem and meropenem. blaTEM, blaSHV, and bla CTX-M were performed for all ESBL-producing isolates. 
Five patterns of ESBL-encoding genes were detected. The most prevalent ESBL-encoding gene was blaTEM; alone in 40% and with other ESBL-
encoding gene(s) in 48% of the isolates. 
Conclusion: High prevalence of ESBL (46%) in our isolates suggesting the need for continuous monitoring of emergence of this pattern in our 
region. 
Keywords: Antimicrobial resistance, Egypt, ESBL, Klebsiella pneumoniae. 
 
INTRODUCTION 
Among the most clinically important β-lactamases are the extended-
spectrum β-lactamases (ESBLs). Infections due to ESBL-producing 
organisms are associated with increased mortality among adults and 
children and are increasing in frequency [1]. Considerable 
proportions of Enterobacteriaceae, including Klebsiella pneumoniae, 
have been observed to harbor ESBLs worldwide [2-4]. K. 
pneumoniae has become an important pathogen in nosocomial 
infections, and its clinical isolates are the major hosts for ESBLs [5, 
6]. ESBL-producing organisms mostly carry self-transferable 
plasmids, which co-transfer enzymes conferring resistance to 
fluoroquinolones, aminoglycosides and tetracyclines [7, 8]. 
Antimicrobial resistance problems in African countries, including 
Egypt, have not been illustrated adequately yet, due to low financial 
resources. Knowledge of the prevalence rates of antimicrobial 
resistance in common nosocomial pathogens in these countries is an 
urgent need to prevent healthcare-associated infections and to 
improve guidelines of empirical antibiotic therapy [9]. TEM and SHV 
ESBLs spread during the 1980s and 1990s, largely in Klebsiella spp. 
and particularly in intensive care units. A massive shift in the 
distribution of ESBLs has occurred since 2000 with the spread of 
CTX-M types [10]. The current study aims to determine the 
prevalence rates of ESBLs in K. pneumonia clinical isolates, mainly 
from cancer patients, from multi-centers in Cairo; Egypt and to 
characterize the ESBL-encoding genes in our isolates.  
MATERIALS AND METHODS 
Selective isolation of microorganisms 
Clinical isolates of K. pneumoniae were collected during a two-year 
period (2011-2012) from four geographically distributed hospitals 
in Cairo, namely, National Cancer Institute (NCI), Naser Medical 
Institute (NMI), National Heart Institute (NHI), and Helwan Hospital 
(HH). Isolates were limited to one per patient, were accepted 
regardless of specimen source and were collected from inpatients 
and outpatients. Upon isolates receipt, they were sub-cultured on 
MacConkey's agar and incubated at 37 °C/24 h. Their taxonomic 
identities were confirmed using standard biochemical tests, as 
follow: pink colonies on MacConkey's agar, black mucoid colonies on 
EMB agar, colorless ether layer in indole test, yellowish color in 
methyl red test, red color in Voges-Proskauer test and blue color 
with growth on citrate medium. Further confirmation of 
identification was performed by Microscan in the faculty of medicine 
laboratories at Cairo University. Pure cultures were emulsified in 
100 µl sterile nutrient broth and 100 µl sterile glycerol using sterile 
cotton swabs and stored in cryovials at -80 oC for long preservation.  
Agar dilution antimicrobial susceptibility testing for ESBL 
screening and for different antimicrobials 
The minimum inhibition concentrations (MICs) of different 
antibiotics were determined by the agar diffusion method according 
to Clinical and Laboratory Standards Institute (CLSI) [11] on Muller-
Hinton agar. Experiments were repeated at least twice for results 
confirmation. Plates were incubated at 37 °C for 18 to 24 h and the 
MICs were calculated. Spots with the lowest concentrations of 
antibiotic showing no growth were defined as the MIC. For ESBL 
screening, a more than 3 two-fold concentration decrease in MIC for 
ceftazidime+clavulanic acid in combination versus ceftazidime alone 
is considered to be positive result for ESBL phenotype [11]. 
Iodometric method for detection of β-lactamases  
Hydrolysis of penicillin yields penicilloic acid, which reduces iodine, 
decolorizes starch-iodine complex within 5 min [12]. This reaction 
can be exploited to detect β-lactamase activity in tubes. Positive and 
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negative controls are vital, as extraneous protein reduces iodine, and 
over-heavily inoculated tests may give false-positive results. 
Confirmatory tests for detection of ESBL in K. pneumoniae 
Escherichia coli ATCC 25922 and K. pneumoniae ATCC 700603 were 
used as a negative and positive control for ESBL test, respectively. The 
double-disk synergy test was performed by a standard disk diffusion 
assay on Muller-Hinton agar following CLSI guidelines. Disks 
containing ceftazidime, ceftriaxone, or cefotaxime (30μg each) were 
placed at distances 30 mm from center to center around a disk 
containing amoxicillin (20μg) plus clavulanic acid (10μg). 
Enhancement of the inhibition zone toward the amoxicillin/ clavulanic 
acid disk was considered suggestive of ESBL production [13]. The 
combination disks (cefotaxime 30μg/clavulanic acid 10μg or 
ceftazidime 30μg/clavulanic acid 10μg) were placed on each plate. 
An organism was interpreted as the ESBL producer if there was an 
increase of ≥5 mm in inhibition zone of the combination disk when 
compared to the corresponding cephalosporin disk alone [11]. 
Plasmid extraction and profiling for ESBL-producing K. pneumoniae 
Examination of plasmid DNA was performed by plasmid DNA 
extraction (Gen Elute plasmid miniprep kit, Sigma) following the 
manufacturer recommendations followed by direct agarose gel 
electrophoresis of extracted DNA [14].  
 
Table 1: Ceftazidime and ceftazidime/clavulanic acid MICs, source of specimen and hospital of isolation for ESBL-producing K. 
pneumoniae isolates 
Hospital Source of specimen  MIC (μg/ml) Isolate code 
Ceftazidime+clavulanic acid  Ceftazidime 
NCI Sputum 4 64 KP1 
NCI Stool 16 512 KP2 
NCI Blood 4 128 KP3 
NCI Blood 2 64 KP4 
NHI Urine 32 512 KP5 
NCI Sputum 16 512 KP6 
NHI Sputum 64 512 KP7 
NCI Sputum 8 256 KP10 
NMI Urine 4 128 KP13 
NCI Blood 2 128 KP16 
NMI Sputum 2 64 KP17 
NCI Sputum 16 256 KP18 
NCI Blood 8 128 KP19 
NMI Urine 4 64 KP20 
NHI Urine 4 128 KP21 
NMI Sputum 8 256 KP25 
HH Urine 8 128 KP28 
NCI Blood 2 32 KP29 
NCI Pus 4 128 KP31 
NCI Urine 16 512 KP34 
NCI Pus 8 128 KP37 
NCI Sputum 4 128 KP39 
NCI Urine 2 32 KP40 
NCI Urine 16 512 KP41 
HH Urine 8 128 KP42 
NHI Sputum 4 64 KP48 
NCI Sputum 8 128  KP50 
NCI Urine 32 256 KP51 
NCI Sputum 8 518 KP53 
NCI Pus  2 64 KP54 
NCI Blood 2 32 KP57 
NCI Blood 8 128 KP59 
NCI Pus 32 1024 KP60 
NCI Stool 32 512 KP64 
NMI Urine 16 128 KP65 
NCI Urine 2 64 KP70 
NCI Sputum 8 256 KP72 
NCI Sputum 8 128 KP73 
NCI Sputum 32 256 KP74 
NCI Urine 16 256 KP75 
NCI Sputum 4 128 KP76 
NCI Sputum 16 256 KP78 
NCI Sputum 8 256 KP79 
NMI Sputum 2 64 KP80 
NHI Urine 4 128 KP81 
NCI Blood 8 256 KP86 
NCI Blood 8 256 KP87 
NCI Pus 4 256 KP90 
NCI Sputum 24 1026 KP91 
NCI Blood 8 512 KP92 
NCI Blood 4 128 KP93 
NCI Blood 8 1024 KP94 
NCI: National Cancer Institute, NMI: Naser Medical Institute, NHI: National Heart Institute, HH: Helwan Hospital 
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DNA template preparation and PCR-based screening for ESBL genes 
Rapid DNA preparation was performed using boiling technique for 
10 min. After centrifugation at 5000 rpm for 5 min, the supernatant 
was used as a template for amplification or stored at -20 °C for later 
use. Screening for the presence of blaTEM, blaSHV, and blaCTX-M genes in 
the ESBL-producing K. pneumoniae was done according to described 
multiplex PCR protocol [15]. The amplification was done using 
Ready Mix™ PCR Reaction Mix (Sigma-Aldrich LP, USA). PCR 
reactions were carried out using 1μl DNA solution, Ready Mix™ PCR 
Reaction Mix (Sigma-Aldrich LP, USA) and 10 p mol of each gene-
specific primer in a final volume of 25μl. PCR amplification 
conditions were as follows: initial denaturation step at 95 °C for 15 
min; 30 cycles of denaturation at 94 °C for 30 s, annealing at 60 °C 
for 30 s, extension at 72 °C for 2 min, followed by a final extension 
step at 72 °C for 10 min. 
RESULTS 
Isolation and identification of K. pneumoniae 
A total of 112 K.pneumoniae isolates were collected from different 
inpatient and outpatient cases in four geographically distributed 
hospitals in Cairo, Egypt. Isolates were collected during a two-year 
period (2011-2012) and identified as K. pneumoniae by Microscan 
and standard biochemical tests. Out of 112 K. pneumoniae isolates, 
75 isolates were collected from NCI “cancer patients”, 15 isolates 
from NHI, 12 isolates from NMI, and 10 isolates from HH.  
 
Table 2: MICs determination of antimicrobial agents against ESBL-producing K. pneumoniae by agar dilution technique 
MICs (µg/ml) of different antimicrobials against tested K. Pneumonia Isolate code 
CIP TET IPM MER AMK GEN SXT FEP 
2 512 1 1 4 512 4/76 32 KP1 
16 1024 1 1 32 1024 1/19 128 KP2 
64 128 1 1 8 8 4/76 512 KP3 
64 512 2 1 8 8 2/38 64 KP4 
128 256 1 1 4 256 2/38 1024 KP5 
128 128 1 1 128 1024 2/38 1024 KP6 
128 256 1 1 16 1024 2/38 1024 KP7 
128 1024 1 1 16 64 4/76 32 KP10 
16 512 1 1 8 8 4/76 32 KP13 
128 256 1 1 2 16 4/76 256 KP16 
128 128 1 1 16 1024 4/76 512 KP17 
32 256 8 8 16 1024 4/76 64 KP18 
2 256 1 1 8 128 4/76 32 KP19 
128 128 1 1 8 1024 4/76 32 KP20 
32 1024 1 1 128 1024 4/76 64 KP21 
128 256 1 1 64 512 4/76 32 KP25 
128 128 1 1 4 256 4/76 64 KP28 
128 256 1 1 64 128 4/76 16 KP29 
32 128 1 1 32 512 4/76 512 KP31 
2 256 1 1 8 128 1/19 1024 KP34 
64 1024 1 1 128 1024 1/19 256 KP37 
128 1024 1 1 2 32 1/19 32 KP39 
16 1024 1 1 32 1024 4/76 64 KP40 
2 1024 1 1 16 1024 4/76 512 KP41 
2 128 1 1 16 1024 4/76 16 KP42 
2 256 1 1 8 256 4/76 32 KP48 
2 128 1 1 4 64 4/76 64 KP50 
2 128 1 1 4 64 4/76 64 KP51 
128 256 1 1 32 128 4/76 256 KP53 
32 1024 1 1 8 1024 2/38 1024 KP54 
64 1024 1 1 4 128 4/76 32 KP57 
128 256 1 1 4 256 4/76 256 KP59 
2 128 1 1 8 1024 4/76 64 KP60 
128 512 1 1 64 1024 2/38 256 KP64 
64 1024 1 1 32 1024 2/38 64 KP65 
128 128 1 1 64 512 2/38 32 KP70 
16 256 1 1 32 1024 4/76 512 KP72 
128 256 1 1 8 256 4/76 256 KP73 
128 128 1 1 8 256 4/76 256 KP74 
64 1024 1 1 64 1024 4/76 32 KP75 
128 256 1 1 64 1024 4/76 256 KP76 
32 1024 8 8 64 1024 4/76 64 KP78 
128 128 1 1 1 8 2/38 512 KP79 
128 1024 1 1 64 1024 2/38 512 KP80 
32 512 1 1 32 1024 2/38 1024 KP81 
64 128 1 1 64 1024 4/76 256 KP86 
32 1024 1 1 2 16 4/76 256 KP87 
128 128 1 1 16 512 4/76 32 KP90 
64 256 1 1 32 512 4/76 512 KP91 
2 1024 1 1 1 8 4/76 32 KP92 
4 128 1 1 128 1024 4/76 32 KP93 
2 256 1 1 8 256 4/76 512 KP94 
FEP: cefepime, SXT: trimethoprim/sulfamethoxazole, GEN: gentamycin, AMK: amikacin, MER: meropenem, IPM: imipenem, TET: tetracycline, CIP: 
ciprofloxacin. 
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Table 3: Number and percentages of resistant isolates in the 52 ESBL-producing K. pneumoniae to tested antimicrobial agents 
Antimicrobial agent Resistant K. Pneumonia 
No. % 
FEP 50 96 
SXT 37 71 
GEN 47 90 
AMK 13 25 
MER 2 4 
IPM 2 4 
CIP 41 79 
TET 100 100 
FEP: cefepime, SXT: trimethoprim/sulfamethoxazole, GEN: gentamycin, AMK: amikacin, MER: meropenem, IPM: imipenem, TET: tetracycline, CIP: 
ciprofloxacin 
 
Screening of ESBLs 
A more than 3 two-fold concentration decrease in MIC for 
ceftazidime in combination with clavulanic acid versus ceftazidime 
MIC alone, when tested by agar dilution method, is considered to be 
positive result for ESBL phenotype according to CLSI 
recommendations. Out of the 112 K. pneumoniae isolates, 52 isolates 
(46%) were identified as ESBL-producing isolates (table 1). 
Of the 52 ESBL-producing K. pneumoniae isolates, 39 isolates (75%) 
were collected from NCI “cancer patients”, 6 isolates (11%) from NMI, 
5 isolates (10%) from NHI, and 2 isolates (4%) from HH. The results 
also show that the prevalence of ESBL-producing K. pneumoniae was 
highest in the NCI hospital, 52 % (39 isolates of 75 isolated from the 
hospital) and was lowest in the HH, 20 % (2 isolates out of 10). 
Whereas, the prevalence of ESBL-producing K. pneumoniae was 50 % 
(6 of 12) and 33% (5 of 15) in NMI and NHI, respectively. Regarding 
the prevalence of ESBL-producing K. pneumoniae among different 
clinical samples, sputum was the most prevalent source (37%) and 
stool was the least prevalent one (4%) (table 1). 
Antimicrobial susceptibility testing for ESBL-producing K. 
pneumonia 
Table 2 shows MICs estimated by agar dilution technique for ESBL-
producing K. pneumoniae for different antimicrobials. 
Interpretation of MICs was performed according to CLSI guidelines. 
The numbers and percentages of resistant isolates in ESBL-
producing K. pneumoniae to the eight tested antimicrobial agents 
were summarized in table 3. All ESBL-producing isolates were 
resistant to tetracycline, whereas two isolates (KP18 and KP78) 
were resistant to carbapenems tested, imipenem and meropenem. 
The two isolates were also resistant to the remaining antimicrobial 
agent tested except isolate KP18 with amikacin. Additionally, most 
of our ESBL-producing K. pneumoniae (96%) were resistant to the 
fourth generation cephalosporin, cefepime. 
Iodometric method for detection of β-lactamases 
The presence of blue color using iodometric method was indicative 
of the β-lactamase production. All ESBL-producing K. pneumoniae 
were positive in the screening of β-lactamases using the iodometric 
method. 
Confirmatory tests for detection of ESBL in K. pneumoniae 
Enhancement of the inhibition zone toward the amoxicillin+ 
clavulanic acid disk was considered suggestive of ESBL production. 
All our 52 ESBL-producing K. pneumoniae isolates were positive for 
this test. Moreover, the combined disk method confirmed ESBL 
production in the 52 K. pneumoniae clinical isolates as evidenced by 
an increase in zone of inhibition of cephalosporin (cefotaxime or 
ceftazidime) plus β-lactamase inhibitor (clavulanic acid) ≥ 5 mm 
than any single cephalosporin. 
Plasmid extraction and profiling for ESBL-producing K. pneumoniae 
The plasmid profiles of all ESBL-producing isolates were analyzed 
by agarose gel electrophoresis. All 52 ESBL-producing K. 
pneumoniae isolates harboured plasmids with different sizes. The 
number of plasmids in each isolate varied from one plasmid to eight 
plasmids (isolate KP28).  
PCR-based screening for ESBL genes 
All 52 positive ESBL-producing K. pneumoniae were examined for 
the prevalence of ESBL-encoding genes by multiplex PCR. The 
results of amplification showed the presence of three bands of 
different sizes, 445bp equivalent to blaTEM, 593bp equivalent to 
blaCTX-M and 747bp equivalent to blaSHV as shown in fig. 1. 
 
 
Fig 1: PCR of the amplified genes with a relative size of 445, 593, 
747 bp for blaTEM, blaCTX-M, and blaSHV, respectively. M: is 
GeneRuler DNA ladder mix (Thermo Scientific, USA). 
 
Five patterns of ESBL-encoding genes were detected in our isolates. 
Among the tested isolates, the most prevalent ESBL-encoding gene 
was blaTEM alone (40%) while the least prevalent pattern of ESBL-
encoding genes was blaCTX-M+blaSHV (2%) (table 4). The blaTEM was 
evident in 46 of 52 isolates (88%) either alone or with other ESBL-
encoding gene(s). 
  
Table 4: Prevalence and pattern of ESBL-encoding genes among ESBL-producing K. pneumoniae 
ESBL-encoding genes pattern of   
blaCTX-M+blaSHV blaCTX-M blaTEM+blaCTX-M+blaSHV blaTEM+blaCTX-M blaTEM 
1 (2%) 5 (10%) 10 (19%) 15 (29%) 21 (40%) Number of isolates harboring ESBL-encoding genes (%) 
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The emergence of ESBLs in K. pneumonia continues to be of critical 
concern for the choice of treatment options against infections caused 
by this bacterium. ESBLs represent the second and a greater 
plasmid-mediated threat to oxyimino-cephalosporins, affecting 
fourth as well as third-generation analogues [10]. The prevalence of 
ESBLs differs among patient groups, harboring bacteria and clinical 
and geographic settings. A recent systematic review about ESBL-
producing Enterobacteriaceae in African studies published 2005 
onwards reported that the proportion of ESBL-producing isolates 
was ˂ 15% in 16 out of 26 studies included in their systematic 
search [9]. They also noticed that ESBLs were more commonly 
identified among Klebsiella spp. than E. coli isolates, which is 
consistent with data from Europe [2].  
Moreover, a study from Egypt detected that 79% of their K. 
pneumoniae isolated from bloodstream infections in intensive 
care units between 2006 and 2007 carry ESBLs [16]. However, it 
should be noted that ESBL acquisition from blood cultures of 
intensive care unit patients with nosocomial infections may 
occur more commonly. In our study, 46 % of K. pneumoniae 
isolates were ESBL producers. This is higher than reported by 
others from Algeria (19.9%) [17], Germany (3%) [18], Italy 
(30%) [19] and Lebanon (20%) [20]. On the other hand, a global 
surveillance database collected from Europe, North and South 
America, and Asia, showed that the detection frequencies for 
ESBL-producing K. pneumoniae isolates were 7.5–44% [21]. In a 
recent study from a cancer center in Japan [22], the ESBL 
producing K. pneumoniae isolated between 2009-2013 
represented only 0.01 per 100 admissions throughout the study 
period. The situation in our study is much worse, where the 
prevalence of ESBL among our K. pneumoniae isolates from 
cancer patients were 52%. 
Our ESBL-producing isolates were also resistant to 
fluoroquinolones, aminoglycosides, tetracycline and trimethoprim/ 
sulfamethoxazole suggesting that ESBL-encoding genes are carried 
on self-transferable plasmid(s) which often carry other genes 
encoding resistance to different drug classes making treatment 
options extremely limited. Among aminoglycosides, amikacin is 
likely to show the greatest percentage of susceptible strains, 
particularly in the United States with the resistance of 
approximately 10%. Amikacin is a likely alternative for empirical 
therapy when other agents cannot be used [23]. In the current study, 
75% of ESBL-producing K. pneumoniae were susceptible to amikacin 
allowing its use as alternative therapy for ESBL-producing 
bacterium. 
The current results show high dissemination of blaTEM gene in our 
isolates (88%) either alone or with other ESBL-encoding gene(s). 
This finding is in contrast to previous reports where blaSHV and 
blaCTX-M was the most prevalent ESBLs [24-26]. 
The present study showed that only two isolates (4%) exhibited 
resistance to the carbapenems tested, imipenem and meropenem 
with MIC value of 8µg/ml. In accordance to our finding, Abdallah et 
al. (2015) [27] noticed that 10 of 15 (66.7%) K. pneumoniae isolated 
from Egypt in 2013 were ESBL producer but none of them was 
resistant to imipenem or meropenem. In contrast, Metwally et al. 
(2013) [28] reported a high prevalence of non-susceptibility to 
imipenem (40%) and meropenem (37.8%) in 45 clinical isolates of 
K. pneumoniae from Egypt during 2011 using CLSI breakpoints of ≥ 2 
µg/ml for both drugs. 
CONCLUSION 
The present study described the prevalence of ESBL-producing K. 
pneumoniae and their encoding genes in multi-centers in Cairo. The 
high carriage rate (46%) of ESBL in our isolates, especially in cancer 
patients, extended our knowledge the worrisome situation of high 
prevalence rates of ESBL-producing Gram-negative organisms 
isolated from hospitals in Egypt [16, 29, 30]. To our knowledge, this 
is the first study reported the incidence of ESBL in K. pneumoniae 
isolated mainly from cancer patients in Egypt. Surveillance of 
emergence and dissemination of ESBL-producing K. pneumoniae is 
an urgent public health need in our region. 
ACKNOWLEDGMENT 
The authors greatly thank the Deanship of Scientific Research at 
King Faisal University (Hofuf, Saudi Arabia) for funding the 
publication through the research project no. 140049. 
CONFLICT OF INTERESTS 
Declared None 
REFERENCES 
1. CurelloJ, MacDougall C. Beyond susceptible and resistant, part 
II: Treatment of infections due to Gram-negative organisms 
producing extended-spectrum β-lactamases. J Pediatr 
Pharmacol Ther 2014;19:156–64. 
2. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-
producing Enterobacteriaceae in Europe. Euro surveillance 
2008;13:pii=19044. 
3. Fennell J, Vellinga A, Hanahoe B, Morris D, Boyle F, Higgins F, et 
al. Increasing prevalence of ESBL production among Irish 
clinical Enterobacteriaceae from 2004 to 2008: an 
observational study. BMC Infect Dis 2012;12:116. 
4. Sankar S, Narayanan H, Kuppanan S, Nandagopal B. Frequency 
of extended spectrum β-lactamase (ESBL)-producing Gram-
negative bacilli in a 200-bed multi-specialty hospital in Vellore 
district, Tamil Nadu, India. Infection 2012;40:425–9. 
5. Bradford PA. Extended-spectrum β-lactamases in the 21st 
century: characterization, epidemiology, and detection of this 
important resistance threat. Clin Microbiol Rev 2001;14:933-51. 
6. Tofteland S, Dahl KH, Aasnæs B, Sundsfjord A, Naseer U. A 
nationwide study of mechanisms conferring reduced 
susceptibility to extended-spectrum cephalosporins in clinical 
Escherichia coli and Klebsiella spp. isolates. Scand J Infect Dis 
2012;44:927-33. 
7. Kang CI, Kim SH, Kim DM, Park WB, Lee KD, Kim HB, et al. Risk 
factors for ciprofloxacin resistance in bloodstream infections 
due to extended-spectrum β-lactamase producing Escherichia 
coli and Klebsiella pneumoniae. Microb Drug Resist 
2004;10:71–6. 
8. Yu WL, Jones RN, Hollis RJ, Messer SA, Biedenbach 
DJ, Deshpande LM, et al. Molecular epidemiology of extended 
spectrum β-lactamase-producing, fluoroquinolone-resistant 
isolates of Klebsiella pneumoniae in Taiwan. J Clin Microbiol 
2002;40:4666–9. 
9. Tansarli GS, Poulikakos B, Kapaskelis A, Falagas ME. Proportion 
of extended-spectrum β-lactamase (ESBL)-producingisolates 
among Enterobacteriaceae in Africa: evaluation of the 
evidence—systematic review. J Antimicrob Chemother 
2014;69:1177–84. 
10. Livermore DM. Current epidemiology and growing resistance of 
gram-negative pathogens. Korean J Intern Med 2012;27:128-42. 
11. Clinical and Laboratory Standards Institute (CLSI). Performance 
standards for antimicrobial susceptibility testing. 23rd. 
informational supplement M100-S23. Wayne, PA: CLSI; 2013. 
12. Catlin BW. Iodometric detection of Haemophilus influenzae 
beta-lactamase: rapid presumptive test for ampicillin 
resistance. Antimicrob Agents Chemother 1975;7:265-70. 
13. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-
spectrum beta-lactamases conferring transferable resistance to 
newer beta-lactam agents in Enterobacteriaceae: hospital 
prevalence and susceptibility patterns. Rev Infect Dis 
1988;10:867-78. 
14. Johnson AP, Burns L, Woodford N, Threlfall EJ, Naidoo J, Cooke 
EM, et al. Gentamicin resistance in clinical isolates of 
Escherichia coli encoded by genes of veterinary origin. J Med 
Microbiol 1994;40:221-6. 
15. Monstein HJ, Ostholm-Balkhed A, Nilsson MV, Nilsson M, 
Dornbusch K, Nilsson LE. Multiplex PCR amplification assay for 
the detection of blaSHV, blaTEM and blaCTX-M genes in 
Enterobacteriaceae. Apmis 2007;115:1400-8. 
16. Saied T, Elkholy A, Hafez SF, Basim H, Wasfy MO, El-Shoubary 
W, et al. Antimicrobial resistance in pathogens causing 
nosocomial bloodstream infections in university hospitals in 
Egypt. Am J Infect Control 2011;39:e61–5. 
El-mahdy et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 12, 122-127 
 
127 
17. Messai Y, Iabadene H, Benhassine T, Alouache S, Tazir 
M, Gautier V, et al. Prevalence and characterization of 
extended-spectrum beta-lactamases in Klebsiella pneumoniae 
in Algiers hospitals (Algeria). Pathol Biol 2008;56:319-25. 
18. Nijssen S, Florijn A, Bonten MJ, Schmitz FJ, Verhoef J, Fluit AC. 
Beta-lactam susceptibilities and prevalence of ESBL-producing 
isolates among more than 5000 European Enterobacteriaceae 
isolates. Int J Antimicrob Agents 2004;24:585-91. 
19. Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori 
E, Leone F, et al. Bloodstream infections caused by extended-
spectrum β-lactamase–producing Klebsiella pneumoniae: risk 
factors, molecular epidemiology, and clinical outcome. 
Antimicrob Agents Chemother 2006;50:498-504. 
20. Daoud Z, Hakime N. Prevalence and susceptibility patterns of 
extended spectrum beta-lactamase–producing Escherichia coli and 
Klebsiella pneumoniae in a general university hospital in Beirut, 
Lebanon. Rev Esp Quimioter 2003;16:233-8. 
21. Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ. 
Antimicrobial susceptibility among organisms from the 
Asia/Pacific Rim, Europe and Latin and North America 
collected as part of TEST and the in vitro activity of tigecycline. 
J Antimicrob Chemother 2007;60:1018–29. 
22. Kawamura I, Ohmagari N, Tsukahara M, Kudo T, Kurai H. 
Surveillance of extended-spectrum β-lactamase-producing 
Escherichia coli and Klebsiella pneumoniae at a comprehensive 
cancer center in Japan, 2009-2013. Am J Infect Control 
2015;43:185-7. 
23. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the 
prevalence of strains expressing an extended-spectrum beta-
lactamase phenotype and characterization of isolates from 
Europe, the Americas, and the Western Pacific region. Clin 
Infect Dis 2001;32 Suppl 2:S94-103. 
24. Mac Aogáin M, Mooij MJ, Adams C, Clair J, O'Gara F. Emergence 
of extended-spectrum beta-lactamase and fluoroquinolone 
resistance genes among Irish multidrug-resistant isolates. 
Diagn Microbiol Infect Dis 2010;67:106-9. 
25. Sabate M, Tarrago R, Navarro F, Miró E, Vergés C, Barbé J, et 
al. Cloning and sequence of the gene encoding a novel 
cefotaxime-hydrolyzing beta-lactamase (CTX-M-9) from 
Escherichia coli in Spain. Antimicrob Agents Chemother 
2000;44:1970-3. 
26. Al-Agamy MH. Phenotypic and molecular characterization of 
extended-spectrum β-lactamases and AmpC β-lactamases in 
Klebsiella pneumoniae. Pak J Pharm Sci 2013;26:291-8. 
27. Abdallah HM, Wintermans BB, Reuland EA, Koek A, al Naiemi 
N, Ammar AM, et al. Extended-spectrum β-Lactamase-and 
carbapenemase-producing Enterobacteriaceae isolated from 
egyptian patients with suspected blood stream infection. PLoS 
One 2015;10:e0128120. 
28. Metwally L, Gomaa N, Attallah M, Kamel N. High prevalence of 
Klebsiella pneumonia carbapenemase-mediated resistance in K. 
pneumoniae isolates from Egypt. East Mediterr Health J 
2013;19:947-52. 
29. Ashour HM, El-Sharif A. Species distribution and antimicrobial 
susceptibility of gram-negative aerobic bacteria in hospitalized 
cancer patients. J Trans Med 2009;7:1-14.30.  
30. El Kholy A, Baseem H, Hall G, Procop W, Longworth L. 
Antimicrobial resistance in Cairo, Egypt 1999-2000: a survey of 
five hospitals. J Antimicrob Chemother 2003;51:625-30. 
 
